Home
About Us
About Us
Board of Directors
Scientific Advisory Board
Management Team
Careers
For Researchers
Paxalisib
EVT801
Collaborating with Kazia
Publications and Presentations
For Partners
Our Current Partners
What We Are Looking For
For Patients
Accessing Kazia Drug Candidates in Clinical Trials
Accessing Kazia Drug Candidates for Compassionate Use
Resources for Patients
For Investors
Press Releases
ASX Announcements
Delisting from ASX
How to convert unlisted shares to ADSs
SEC Filings
Corporate Presentations
Annual Reports
Financial Reports
AGM
Corporate Governance
Shareholder Services
Media Centre
Overview
Video
Coverage
Contact
Contact Us
Subscribe to email alerts
Home
/
Media Centre
/
Coverage
Overview
Video
Coverage
Recent Posts
Kazia Therapeutics says diversification is the key to drug development
Kazia Therapeutics’ oncology drug paxalisib continues to generate positive trial data
Kazia Therapeutics' promising data on treatment targeting brain metastases to be presented at conference
Kazia Therapeutics forms new Scientific Advisory Board with world-leading experts in brain cancer
Kazia Therapeutics gains US FDA Rare Paediatric Disease Designation for paxalisib in rare form of childhood brain cancer
Archives
August 2022
July 2022
June 2022
May 2022
April 2022
February 2022
December 2021
November 2021
October 2021
September 2021
July 2021
April 2021
February 2021
December 2020
October 2020
September 2020
August 2020
July 2020
June 2020
May 2020
Categories
GENERAL
MEDIA RELEASE
Uncategorized
Dr James Garner speaks with CommSec re our GDC-0084 Phase II trial start
Posted in
Uncategorized
